Krystal Biotech (KRYS) Liabilities and Shareholders Equity (2016 - 2026)

Krystal Biotech has reported Liabilities and Shareholders Equity for 11 years, with the latest figure at $1.5 billion in Q2 2026.

• Liabilities and Shareholders Equity for Q2 2026 came in at $1.5 billion, up 31.82% year-over-year; the trailing twelve-month figure through Jun 2026 was $5.5 billion (up 28.71% YoY), and the FY2025 annual result was $1.3 billion, up 26.33% from the prior year.
• Liabilities and Shareholders Equity rose to $1.5 billion in Q2 2026, from $1.4 billion in the prior quarter.
• Over five years, Liabilities and Shareholders Equity peaked at $1.5 billion in Q2 2026 and troughed at $531.8 million in Q1 2023.
• A 5-year average of $926.2 million and a median of $885.5 million in 2024 frame the typical range for Liabilities and Shareholders Equity.
• The widest annual swing landed in 2023, when Liabilities and Shareholders Equity decreased 13.78%; it then surged 60.44% in 2024.
• A 5-year view of Liabilities and Shareholders Equity shows it stood at $558.4 million in 2022, then jumped by 46.54% to $818.4 million in 2023, then advanced by 29.02% to $1.1 billion in 2024, then increased by 26.33% to $1.3 billion in 2025, then increased by 12.51% to $1.5 billion in 2026.
• Per Business Quant data, the three most recent Liabilities and Shareholders Equity figures were $1.5 billion in Q2 2026, $1.4 billion in Q1 2026, and $1.3 billion in Q4 2025.